SEC 13F Intelligence

Deuterium Capital Management, LLC / NKTR

Deuterium Capital Management, LLC’s Nektar Therapeutics Position

Does Deuterium Capital Management, LLC own Nektar Therapeutics (NKTR)? Yes — 18.0K shares worth $1M (+1.51% of its 13F portfolio) as of Q1 2026, down from 37.3K shares the prior filed quarter.

Position Value
$1M
Q1 2026
Shares
18.0K
% of Portfolio
+1.51%
Quarters Held
4
currently held

Position History NKTR

Reported value by quarter
Q2 ’25: $965,098Q2 ’25Q3 ’25: $2MQ3 ’25Q4 ’25: $2MQ4 ’25Q1 ’26: $1MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 202618.0K$1M+1.51%
Q4 202537.3K$2M+2.29%
Q3 202537.3K$2M+3.08%
Q2 202537.3K$965,098+1.81%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Deuterium Capital Management, LLC’s full portfolio or all institutional holders of NKTR.